About Valeritas
Valeritas is a company based in Bridgewater (United States) founded in 2003 was acquired by Zealand Pharma in February 2020. Valeritas has raised $181.36 million across 6 funding rounds from investors including Welsh, Carson, Anderson & Stowe, Zealand Pharma and Abingworth. The company has 141 employees as of December 31, 2019. Valeritas has completed 1 acquisition, including Andover. Valeritas offers products and services including Afrezza, V-Go, and Technosphere. Valeritas operates in a competitive market with competitors including scPharmaceuticals, Crossject, CeQur, Vaxxas and Incline Therapeutics, among others.
- Headquarter Bridgewater, United States
- Employees 141 as on 31 Dec, 2019
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mannkind Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$181.36 M (USD)
in 6 rounds
-
Latest Funding Round
$25.2 M (USD), Post-IPO
May 04, 2016
-
Investors
Welsh, Carson, Anderson & Stowe
& 13 more
-
Employee Count
141
as on Dec 31, 2019
- Investments & Acquisitions
-
Acquired by
Zealand Pharma
(Feb 10, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Valeritas
Valeritas offers a comprehensive portfolio of products and services, including Afrezza, V-Go, and Technosphere.
Inhaled powder for managing diabetes blood sugar levels.
Patch device for continuous insulin administration.
Platform for delivering drugs via inhalation.
People of Valeritas
Unlock access to complete
Funding Insights of Valeritas
Valeritas has successfully raised a total of $181.36M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.2 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Valeritas
Valeritas has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Welsh, Carson, Anderson & Stowe, Zealand Pharma and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Locked | Locked | Locked | |
|
Early-stage investments in US tech and life sciences are targeted.
|
Locked | Locked | Locked | |
|
Venture capital investments in tech and healthtech sectors through dedicated funds.
|
Locked | Locked | Locked |
Investor details for Valeritas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Valeritas
Valeritas has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Andover.
Investment portfolio details for Valeritas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Limited information is provided on core activities.
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for Valeritas
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Valeritas
Detailed financials for Valeritas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Valeritas Comparisons
Peer comparison for Valeritas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Valeritas
Valeritas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as scPharmaceuticals, Crossject, CeQur, Vaxxas and Incline Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| Locked | Locked | Locked |
Needle-free self-injectable drugs
|
|
| Locked | Locked | Locked |
Wearable insulin delivery patches are developed for mealtime dosing.
|
|
| Locked | Locked | Locked |
Developer of vaccines to treat cancer and infectious diseases
|
|
| Locked | Locked | Locked |
Hospital-focused specialty pharmaceuticals are developed for acute pain management.
|
Detailed competitors of Valeritas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Valeritas
Complete news archive for Valeritas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Valeritas
Valeritas was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Valeritas is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Valeritas is a funded company, having raised a total of $181.36M across 6 funding rounds to date.
As of Dec 31, 2019, the latest employee count at Valeritas is 141.
Valeritas was founded in 2003 in Bridgewater, United States, within the medical devices sector focused on diabetes management. Wearable insulin patch pumps are produced for skin-based insulin delivery, holding a one-day supply of fast-acting insulin. Continuous preset basal rates are used for release, supplemented by on-demand bolus dosing at mealtimes. Programmability and electricity are not required in the devices, with preset options available for varying daily insulin amounts.
Valeritas's top competitors include scPharmaceuticals, Crossject and Vaxxas.
Valeritas offers Afrezza, V-Go, and Technosphere.
Valeritas has made 1 acquisition, including Andover.
Valeritas has 14 investors. Key investors include Welsh, Carson, Anderson & Stowe, Zealand Pharma, Abingworth, CRG, and Montrose Capital Partners.